Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1217 participants
INTERVENTIONAL
2004-12-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Primary objective: To evaluate in patients with advanced follicular lymphoma the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy
* Secondary objective: To evaluate response rates, event driven survival endpoints (EFS, PFS, OS) and quality of life of four different chemotherapy regimens combined with rituximab, with or without maintenance with rituximab, for first line treatment of advanced stage follicular lymphoma.
* Study Design This is an international open-label, multicentre, randomized study with two treatment phases. In the induction phase patients have to respond to 1st line induction treatment in order to be eligible for randomization to the second phase of maintenance treatment or observation. After the maintenance period patients will be included in the follow up phase for 3 years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
NCT02569996
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
NCT01200758
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
NCT01684865
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* First period: Induction of response with 8 x rituximab combined with 8 cycles of CVP or 6 cycles of CHOP in 21-day cycles or 6 cycles of FCM in 28-day cycles or 6 cycles of MCP in 28-day cycles.
* Second period: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A : rituximab maintenance
Maintenance with rituximab for 2 years
Rituximab
rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
B : no maintenance
No further treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab
rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients previously untreated.
* Patients with at least one of the following symptoms requiring initiation of treatment:
* Bulky disease at study entry according to the GELF criteria: nodal or extranodal mass \> 7cm in its greater diameter
* B symptoms
* Elevated serum LDH or beta2-microglobulin
* involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)
* symptomatic splenic enlargement
* compressive syndrome
* pleural/peritoneal effusion
* Age must be \> 18 years.
* Performance status \< 2 on the ECOG scale (see appendix E).
* Adequate hematological function within 28 days prior to registration (unless those abnormalities are related to lymphoma extension), this includes:
* Hemoglobin ≥ 8.0 g/dl (5.0 mmol/L)
* Absolute neutrophil count (ANC) ≥ 1.5 109/L
* Platelet count ≥ 100 109/L
* Women are not breast feeding, are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.
* Having previously signed a written informed consent form.
Exclusion Criteria
* Grade 3b follicular lymphoma.
* Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis).
* Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to \< 20 mg/day prednisone.
* Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.
* Major surgery (excluding lymph node biopsy) within 28 days prior to registration.
* Poor renal function: Serum creatinine \> 2.0 mg/dl (197 μmol/L),
* Poor hepatic function: total bilirubin \> 2.0 mg/dl (34 μmol/L), AST (SGOT) \> 3 x the upper limit of normal unless these abnormalities are related to lymphoma.
* Known HIV infection or active HBV or HCV infection.
* Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
* Life expectancy \< 6 months
* Known sensitivity or allergy to murine products
* Treatment within a clinical trial within 30 days prior to trial entry
* Adult patient under tutelage.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HOVON - Dutch Haemato-Oncology Association
OTHER
German Low Grade Lymphoma Study Group
OTHER
Australasian Leukaemia and Lymphoma Group
OTHER
Institute of Cancer Research, United Kingdom
OTHER
Lymphoma Study Association
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles A Salles, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundaleu Hospital
Buenos Aires, , Argentina
Australian Leukemia and Lymphoma Group
Melbourne, , Australia
Université de Gent
Ghent, , Belgium
Groupe d'Etude des Lymphomes de l'adulte
Mont-Godinne, , Belgium
Hospital Samaritano
São Paulo, , Brazil
Fundación Santafé de Bogotá
Bogotá, , Colombia
Amtssygehuset i Herlev
Herlev, , Denmark
Polyclinique Bordeaux Nord
Bordeaux, , France
Hôpital Henri Mondor
Créteil, , France
Hématologie CHU de Lille
Lille, , France
Centre Léon Bérard
Lyon, , France
Institut Curie
Paris, , France
Hôpital Saint Louis
Paris, , France
Hématologie Adultes - Hôpital Necker
Paris, , France
Service d'Hématologie - Centre Hospitalier Lyon-Sud
Pierre-Bénite, , France
Centre Hospitalier Robert Debré
Reims, , France
Centre Henri Becquerel
Rouen, , France
Hématologie CHU Purpan
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
HOVON
Utrecht, , Netherlands
Australia New Zealand Leukemia Lymphoma Group
Auckland, , New Zealand
Instituo Nacional de Enfermedades Neoplasicas
Lima, , Peru
Hospital Clinic Barcelona
Barcelona, , Spain
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bachy E, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24.
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. doi: 10.1179/1607845414Y.0000000179. Epub 2014 Jul 16.
Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012 Sep 27;120(13):2650-7. doi: 10.1182/blood-2012-05-431825. Epub 2012 Aug 10.
Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferme C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRIMA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.